Newron Secures Funding to Advance Schizophrenia Treatment Pipeline

Newron Pharmaceuticals raises up to €38M in milestone-based financing to fund late-stage trials for Evenamide in therapy-resistant schizophrenia, extending cash runway to 2027.

Biopharmaceutical firm Newron Pharmaceuticals has successfully arranged a substantial financial package to support the late-stage development of its lead drug candidate, Evenamide. The company, which specializes in therapies for central nervous system disorders, has secured access to up to €38 million in new capital, a move that strengthens its balance sheet as it progresses key clinical trials.

Funding Tied to Clinical Milestones

The financing agreement is structured in multiple tranches, with disbursements directly linked to achieving specific clinical development goals. An initial investment of approximately €15 million was raised through the issuance of nearly 780,000 new shares at a price of €19.24 per share. A further €23 million is contingent upon positive results from the pivotal ENIGMA-TRS studies, which are essential for regulatory approval. Combined with ongoing revenue from its marketed Parkinson's disease drug, Xadago, Newron estimates its financial runway now extends into early 2027.

On the market, Newron's shares are currently trading at €18.18, slightly below the price of the recent placement. Despite a weak start to the year, the stock has delivered impressive gains for investors, appreciating by more than 94% over the preceding twelve-month period.

Extended Patent Protection and Clinical Focus

In a parallel strategic development, the company has fortified its intellectual property position. The European Patent Office has granted a new patent covering specific crystalline forms of Evenamide and their manufacturing processes. This protection is now set to last until 2044, providing long-term exclusivity for the compound.

Operationally, Newron's resources are concentrated on three global Phase III clinical trials involving over 1,000 patients. Evenamide is being developed as a treatment for therapy-resistant schizophrenia. It employs a distinct mechanism of action, modulating the brain's glutamate system, unlike conventional antipsychotic medications.

The path forward is clearly charted. The company anticipates receiving critical 12-week analysis data from its clinical program in the fourth quarter of 2026. These results will be a primary determinant in securing regulatory approval for Evenamide as an adjunctive therapy and will trigger the release of the remaining funds from the current financing agreement.